Open AccessPrimary resistance to alectinib in a patient with STRN‐ALK ‐positive non‐small cell lung cancer: A case report
Author(s) -
Sun Kunyan,
Nie Ligong,
g Lin,
Cheng Yuan
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13983
Subject(s) - alectinib , crizotinib , anaplastic lymphoma kinase , medicine , lung cancer , alk inhibitor , cancer research , ceritinib , receptor protein tyrosine kinases , tyrosine kinase , tyrosine kinase inhibitor , oncology , cancer , receptor , malignant pleural effusion
Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However, the response of patients with rare ALK rearrangements to tyrosine kinase inhibitors remains unknown. Here, we report a rare case of striatin (STRN)‐ALK‐positive NSCLC showing primary resistance to first‐line therapy alectinib and limited clinical activity of crizotinib in the alectinib‐resistant setting.